Search Results | Cancer Research | American Association for Cancer Research

1-20 of 50

2 3

Sort by

Sort Order Select

Journal Articles

Abstract 3139: Disrupting prostaglandin E₂ signaling to reverse treatment resistance in cancer

Nune Markosyan, Liz Quinones, Charu Aurora, Nikhil Joshi, Ilkyu Kim, Ben Z. Stanger, Robert H. Vonderheide

Cancer Res (2022) 82 (12_Supplement): 3139.

DOI: https://doi.org/10.1158/1538-7445.AM2022-3139

Published: 15 June 2022

View article

Journal Articles

Abstract 4188: CD4+ T cells mediate non-canonical rejection of major histocompatibility class-I deficient pancreatic tumors independently of CD8+ T cells

Samuel I. Kim, Charu Arora, Ioannis I. Verginadis, Christopher R. Cassella, Nune Markosyan, Constantinos Koumenis, Robert H. Vonderheide, Katelyn T. Byrne

Cancer Res (2022) 82 (12_Supplement): 4188.

DOI: https://doi.org/10.1158/1538-7445.AM2022-4188

Published: 15 June 2022

View article

Journal Articles

Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial

Cancer Res (2021) 81 (13_Supplement): CT005.

DOI: https://doi.org/10.1158/1538-7445.AM2021-CT005

Published: 01 July 2021

View article

Journal Articles

Abstract 2723: How BRCA1/2 mutations in TNBC affect TME and subsequently immune cell functions

Dana Pueschl, Derek A. Oldrige, Jonathan Belman, Jake S. Shilan, Anupma Nayak, Bradley Wubbenhorst, John Pluta, Robert H. Vonderheide, Michael Feldman, Kara N. Maxwell, E. John Wherry, Susan M. Domchek, Katherine L. Nathanson

Cancer Res (2021) 81 (13_Supplement): 2723.

DOI: https://doi.org/10.1158/1538-7445.AM2021-2723

Published: 01 July 2021

View article

Journal Articles

Abstract 1899: Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

Adham S. Bear, Tatiana Blanchard, Mark H. O'Hara, John Scholler, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno

Cancer Res (2021) 81 (13_Supplement): 1899.

DOI: https://doi.org/10.1158/1538-7445.AM2021-1899

Published: 01 July 2021

View article

Journal Articles

Abstract PR-003: Tumor-cell-intrinsic epigenetic factors underlie the heterogeneity of immune infiltration and response to immunotherapy in pancreatic cancer

Jinyang Li, Salina Yuan, Robert J. Norgard, Fangxue Yan, Robert H. Vonderheide, Andres Blanco, Ben Z. Stanger

Cancer Res (2020) 80 (22_Supplement): PR-003.

DOI: https://doi.org/10.1158/1538-7445.PANCA20-PR-003

Published: 13 November 2020

View article

Journal Articles

Abstract LB-077: Dendritic cell dysfunction precedes tumor formation during pancreatic oncogenesis

Jeffrey H. Lin, Robert H. Vonderheide

Cancer Res (2020) 80 (16_Supplement): LB-077.

DOI: https://doi.org/10.1158/1538-7445.AM2020-LB-077

Published: 15 August 2020

View article

Journal Articles

Abstract I12: CD40 immunotherapy for pancreatic cancer

Robert H. Vonderheide

Cancer Res (2019) 79 (24_Supplement): I12.

DOI: https://doi.org/10.1158/1538-7445.PANCA19-I12

Published: 13 December 2019

View article

Journal Articles

Abstract A28: Investigation of tumor-cell-intrinsic factors regulating immune infiltration and response to immunotherapy in pancreatic cancer

Jinyang Li, Katelyn T Byrne, Nune Markosyan, Taiji Yamazoe, Fangxue Yan, Zeyu Chen, Yu H. Sun, Jeffrey Lin, Yogev Sela, Robert J. Norgard, Salina Yuan, Allyson J. Merrell, John W. Tobias, Robert H. Vonderheide, Ben Z. Stanger

Cancer Res (2019) 79 (24_Supplement): A28.

DOI: https://doi.org/10.1158/1538-7445.PANCA19-A28

Published: 13 December 2019

View article

Journal Articles

Abstract PR04: STING and TLR-independent activation of T-cell responses against pancreatic cancer using agonistic CD40 antibody

Katelyn T. Byrne, Alexander H. Morrison, Robert H. Vonderheide

Cancer Res (2019) 79 (24_Supplement): PR04.

DOI: https://doi.org/10.1158/1538-7445.PANCA19-PR04

Published: 13 December 2019

View article

Journal Articles

Abstract B31: Type 1 conventional dendritic cells are progressively and systemically dysregulated early in pancreatic carcinogenesis

Jeffrey H. Lin, Austin P. Huffman, Emma E. Furth, Robert H. Vonderheide

Cancer Res (2019) 79 (24_Supplement): B31.

DOI: https://doi.org/10.1158/1538-7445.PANCA19-B31

Published: 13 December 2019

View article

Journal Articles

Abstract C13: A “mouse hospital” for preclinical testing of diagnostic and treatment modalities in pancreatic ductal adenocarcinoma (PDA)

Cynthia Clendenin, Rina Sor, Deirdre McMenamin, Ben Z. Stanger, Gregory Beatty, Robert H. Vonderheide

Cancer Res (2019) 79 (24_Supplement): C13.

DOI: https://doi.org/10.1158/1538-7445.PANCA19-C13

Published: 13 December 2019

View article

Journal Articles

Abstract B04: Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer

Adham S. Bear, Andrew J. Rech, Lee P. Richman, Mark H. O'Hara, Gerald P. Linette, Beatriz M. Carreno, Robert H. Vonderheide

Cancer Res (2019) 79 (24_Supplement): B04.

DOI: https://doi.org/10.1158/1538-7445.PANCA19-B04

Published: 13 December 2019

View article

Journal Articles

Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients

Cancer Res (2019) 79 (13_Supplement): CT004.

DOI: https://doi.org/10.1158/1538-7445.AM2019-CT004

Published: 01 July 2019

View article

Journal Articles

Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer

Andrew J. Rech, Hannah Dada, Jonathan J. Kotzin, Jorge Henao-Mejia, Andy J. Minn, Christina Twyman-Saint Victor, Robert H. Vonderheide

Cancer Res (2018) 78 (15): 4282–4291.

DOI: https://doi.org/10.1158/0008-5472.CAN-17-3821

Published: 31 July 2018

View article

Includes: Supplementary data

Journal Articles

Abstract 2985: Radiotherapy and αCD40 non-redundantly augment immunity to checkpoint blockade in refractory pancreatic ductal adenocarcinoma

Hannah Dada, Andrew J. Rech, Christina Twyman-Saint Victor, Andy J. Minn, Robert H. Vonderheide

Cancer Res (2018) 78 (13_Supplement): 2985.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2985

Published: 01 July 2018

View article

Journal Articles

Abstract 1011: Tumor cell intrinsic factors dictate T cell infiltration and therapeutic response in pancreatic ductal adenocarcinoma

Katelyn T. Byrne, Jinyang Li, Robert H. Vonderheide, Ben Z. Stanger

Cancer Res (2018) 78 (13_Supplement): 1011.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1011

Published: 01 July 2018

View article

Journal Articles

Abstract 4940: Nonredundant roles for immune checkpoint blockade and agonistic CD40 in mediating T-cell responses in pancreatic ductal adenocarcinoma

Alexander H. Morrison, Katelyn T. Byrne, Robert H. Vonderheide

Cancer Res (2018) 78 (13_Supplement): 4940.

DOI: https://doi.org/10.1158/1538-7445.AM2018-4940

Published: 01 July 2018

View article

Journal Articles

Abstract 3691: Analysis of germline BRCA1/2 mutation associated breast and ovarian tumors reveals distinct pathways of immunosuppression

Adam Kraya, Kara N. Maxwell, Brandon M. Wenz, Bradley Wubbenhorst, Nicole Lunceford, Amanda Barrett, Jennifer J. Morrissette, Michael D. Feldman, Susan M. Domchek, Robert H. Vonderheide, Katherine L. Nathanson

Cancer Res (2017) 77 (13_Supplement): 3691.

DOI: https://doi.org/10.1158/1538-7445.AM2017-3691

Published: 01 July 2017

View article

Journal Articles

Abstract SY25-02: Antigenic strength vs. tumor microenvironment in determining cancer immunosurveillance

Robert H. Vonderheide

Cancer Res (2017) 77 (13_Supplement): SY25-02.

DOI: https://doi.org/10.1158/1538-7445.AM2017-SY25-02

Published: 01 July 2017

View article

2 3

NARROW

Abstract 3139: Disrupting prostaglandin E₂ signaling to reverse treatment resistance in cancer

Abstract 4188: CD4+ T cells mediate non-canonical rejection of major histocompatibility class-I deficient pancreatic tumors independently of CD8+ T cells

Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial

Abstract 2723: How BRCA1/2 mutations in TNBC affect TME and subsequently immune cell functions

Abstract 1899: Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

Abstract PR-003: Tumor-cell-intrinsic epigenetic factors underlie the heterogeneity of immune infiltration and response to immunotherapy in pancreatic cancer

Abstract LB-077: Dendritic cell dysfunction precedes tumor formation during pancreatic oncogenesis

Abstract I12: CD40 immunotherapy for pancreatic cancer

Abstract A28: Investigation of tumor-cell-intrinsic factors regulating immune infiltration and response to immunotherapy in pancreatic cancer

Abstract PR04: STING and TLR-independent activation of T-cell responses against pancreatic cancer using agonistic CD40 antibody

Abstract B31: Type 1 conventional dendritic cells are progressively and systemically dysregulated early in pancreatic carcinogenesis

Abstract C13: A “mouse hospital” for preclinical testing of diagnostic and treatment modalities in pancreatic ductal adenocarcinoma (PDA)

Abstract B04: Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer

Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients

Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer

Abstract 2985: Radiotherapy and αCD40 non-redundantly augment immunity to checkpoint blockade in refractory pancreatic ductal adenocarcinoma

Abstract 1011: Tumor cell intrinsic factors dictate T cell infiltration and therapeutic response in pancreatic ductal adenocarcinoma

Abstract 4940: Nonredundant roles for immune checkpoint blockade and agonistic CD40 in mediating T-cell responses in pancreatic ductal adenocarcinoma

Abstract 3691: Analysis of germline BRCA1/2 mutation associated breast and ovarian tumors reveals distinct pathways of immunosuppression

Abstract SY25-02: Antigenic strength vs. tumor microenvironment in determining cancer immunosurveillance

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only